Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PFE (Pfizer) How high will it go? -- Ignore unavailable to you. Want to Upgrade?

To: Chung Lee who wrote (1689)	4/27/1998 4:49:00 PM
From: Anthony Wong	Read Replies (1) \| Respond to of 9523

Pfizer's Viagra Grabs Almost 95% Of Impotence Market April 27, 1998 3:29 PM WASHINGTON (Dow Jones)--Pfizer Inc.'s (PFE) Viagra grabbed almost 95% of the bulk of new impotence drug prescriptions in only its third week on the market. Popular with men because it comes in pill form, Viagra accounted for 94.4% of all new prescriptions written in the "sexual dysfunction disorder" category, according to IMS Health, a healthcare auditor. Viagra charged ahead of the former market leaders, Vivus Inc.'s (VVUS) Muse and Pharmacia & Upjohn Inc.'s (PNU) Caverject, in its second week. Last year's No. 1 impotence treatment, Muse, was left with 3.8% of new prescriptions. Caverject, last year's second-selling treatment, had 1.5%. -Otesa Middleton; 202-862-6654